Possibility of membrane modification as a mechanism of antimony resistance in Leishmania donovani.
Resistance to antimonials has become a clinical threat in the treatment of visceral leishmaniasis (VL). Unravelling the resistance mechanism needs attention to circumvent the problem of drug resistance. In one of the resistant isolates, we earlier identified a gene (PG1) implicated in antimony resistance whose localization in the present study was confirmed on the pellicular plasma membrane of the parasite thereby indicating towards membrane modification as a mechanism of resistance in this resistant isolate.
Kothari
Hema
H
Drug Target Discovery and Development Division, Central Drug Research Institute, Lucknow, India.
Kumar
Pranav
P
Sundar
Shyam
S
Singh
Neeloo
N
D000818:Animals; D000965:Antimony / Q000494:pharmacology* / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015152:Blotting, Northern; D002462:Cell Membrane / Q000187:drug effects* / Q000378:metabolism; D004351:Drug Resistance; D017125:Genes, Protozoan; D007893:Leishmania donovani / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000469:parasitology; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism; D015800:Protozoan Proteins / Q000235:genetics / Q000378:metabolism; D016053:RNA, Protozoan / Q000235:genetics
D000981:Antiprotozoal Agents; D008565:Membrane Proteins; D015800:Protozoan Proteins; D016053:RNA, Protozoan; D000965:Antimony